Closed · W81XWH-16-LCRP-CEA · CFDA 12.420 · Discretionary

DoD Lung Cancer Research Program Clinical Exploration Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
September 14, 2016
Close date
2
Expected awards

The verdict

DoD Lung Cancer Research Program Clinical Exploration Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 2 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
2
expected awards
12.420
CFDA program

Archived opportunity record

DoD Lung Cancer Research Program Clinical Exp… is closed (last close September 14, 2016). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed September 14, 2016

Posted Apr 11 Closes Sep 14

Est. Total Funding

$1,760,000

Expected Awards

2

Instrument

Grant

Description

The Clinical Exploration Award (CEA) mechanism supports rapid execution of early-phase, proof-of-principle clinical trials to examine hypothesis-based, innovative interventions that have the potential to resolve current clinical barriers and result in a profound impact on the clinical management of lung cancer. While therapeutic approaches proposed for testing through the CEA must represent novel, hypothesis-based, “outside-the-box” approaches for treating lung cancer, they may include therapies already in clinical use, or undergoing clinical testing for other diseases, provided that the proposed use for lung cancer would lead to a major advancement for treating the disease. Outcomes from studies funded by this award are anticipated to provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform lung cancer clinical care. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Clinical Trials: The CEA supports clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drug or drug combinations, Class II or III devices, or other types of trials that conduct early clinical testing of innovative approaches for lung cancer. Information on clinical trials and phases/classes of study is provided in the “Human Subject Resource Document” available for download from eBRAP at https://ebrap.org/eBRAP/public/Program.htm. Projects that only propose correlative studies from ongoing or completed clinical trials are not allowed. Investigators wishing to apply for funding for correlative studies should consider submitting an application to the FY16 LCRP Investigator-Initiated Translational Research Award mechanism (Funding Opportunity Number: W81XWH-16-LCRP-IITRA). Because the CEA seeks to support highly innovative, high-impact early-phase clinical trials with near-term clinical relevance, it is the responsibility of the PI to clearly articulate how the proposed study represents research that is beyond conventional therapeutic approaches for lung cancer. Studies in a broad range of areas related to lung cancer clinical management will be considered under the CEA, including but not limited to, evaluation of drugs, biologics, devices, surgical procedures, behavior modifications, or other types of therapeutic approaches. Key elements of this award are as follows: • The application should clearly specify the type of clinical study, including phase or class designation (if applicable), that is being proposed. • The application must include documentation of an existing Investigational New Drug (IND) or Investigational Device Exemption (IDE), if applicable. • The proposed intervention must be based on sound scientific rationale that is established through logical reasoning, critical review and analysis of the literature, and preliminary data. • The application should demonstrate availability and accessibility of a suitable human subject population that will support a meaningful outcome for the study. • The application must demonstrate documented availability and accessibility of the drug/compound, device, and/or other materials needed, e.g., a letter from the manufacturer assuring an adequate supply of the agent (and placebo, if necessary). • The proposed study should include clearly defined and appropriate endpoints. • The application should include a detailed statistical analysis plan, including a power analysis reflecting sample size projections that will clearly answer the objectives of the study. • The proposed study is expected to begin no later than 12 months after the award date. • The application should include a Transition Plan that describes a clear path for further clinical development. • Relevance to Military Beneficiaries: The application should clearly articulate how the proposed research is relevant to military Service members, Veterans, and their families.

Catch-all / unrestricted eligibility mark · W81XWH-16-LCRP-CEA

Grants.gov marks DoD Lung Cancer Research Program Clinical Exp… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

What to do next

DoD Lung Cancer Research Program Clinical Exp… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants